Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, 00146 Rome, Italy.
Int J Mol Sci. 2020 Jul 21;21(14):5145. doi: 10.3390/ijms21145145.
Coronavirus 2 (CoV) Severe Acute Respiratory Syndrome (SARS-CoV2) is causing a highly infectious pandemic pneumonia. Coronaviruses are positive sense single-stranded RNA viruses that infect several animal species, causing symptoms that range from those similar to the common cold to severe respiratory syndrome. The Angiotensin Converting Enzyme 2 (ACE2) is the SARS-CoV2 functional receptor. Measures are currently undertaken worldwide to control the infection to avoid disruption of the social and economic equilibrium, especially in countries with poor healthcare resources. In a guarded optimistic view, we hope that the undertaken preventive and treatment measures will at least contribute to contain viral diffusion, attenuate activity, or even eliminate SARS-CoV2. In this review, we discuss emerging perspectives for prevention/treatment of COVID-19 infection. In addition to vaccines under development, passive immunization is an open opportunity since patients develop neutralizing antibodies. A full spectrum of potential drugs for COVID-19 infections could in turn affect virus binding or enzymatic activities involved in viral replication and transcription. Furthermore, clinical trials are currently evaluating the safety and efficacy of anti-inflammatory drugs, such as tocilizumab. Bioinformatics may allow characterization of specific CD8+ and CD4+ T cell responses; thus, CoV2 T cells' frequency can be correlated with the disease severity and outcome. Combinatorial antibody phage display may be empowered to identify the immune repertoire of CoV2-specific neutralizing antibodies.
冠状病毒 2(CoV)严重急性呼吸系统综合征(SARS-CoV2)正在引发高度传染性的大流行肺炎。冠状病毒是感染多种动物物种的正链单链 RNA 病毒,引起的症状从类似于普通感冒到严重呼吸系统综合征不等。血管紧张素转换酶 2(ACE2)是 SARS-CoV2 的功能性受体。目前全球正在采取措施控制感染,以避免社会和经济平衡受到干扰,特别是在医疗资源匮乏的国家。从谨慎乐观的角度来看,我们希望所采取的预防和治疗措施至少有助于遏制病毒扩散、减轻其活性,甚至消灭 SARS-CoV2。在这篇综述中,我们讨论了 COVID-19 感染的预防/治疗的新观点。除了正在开发的疫苗外,被动免疫也是一个开放的机会,因为患者会产生中和抗体。一系列针对 COVID-19 感染的潜在药物可能会影响病毒结合或参与病毒复制和转录的酶活性。此外,临床试验目前正在评估抗炎药物(如托珠单抗)的安全性和疗效。生物信息学可能允许对特定的 CD8+和 CD4+T 细胞反应进行特征描述;因此,CoV2 T 细胞的频率可以与疾病的严重程度和结果相关联。组合抗体噬菌体展示技术可能有助于识别 CoV2 特异性中和抗体的免疫库。